The FDA granted Fast Track designation for treatments, and the company Oncolytics Biotech began using LinkedIn for its social media presence.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted Fast Track designation for treatments, and the company Oncolytics Biotech began using LinkedIn for its social media presence.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Oncolytics Biotech
Nothing else this week.
-
LinkedIn
American social networking website for people in professional occupations
Related events
- Edgewise Therapeutics announced news from Boulder, Colorado, and utilizes LinkedIn for its public communication.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- Experimental therapies require approval from the FDA.
- Legend Biotech and Johnson & Johnson announced their collaboration on CARVYKTI, while Legend Biotech also utilized LinkedIn for professional presence.
- FDA granted Fast Track designation to NRX-100 on September 4, 2025.
Coverage
Newest first; wire copies grouped- CNW GroupOncolytics Biotech® Announces Upcoming Investor Conferences in September SAN DIEGO, Aug. 28, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage im